Rct Evidence
Research
A 2025–2026 randomized, double-blind, placebo-controlled trial (NCT04019197, n=84) published in Nature Communications provides the first RCT evidence that once-weekly semaglutide measurably slows biological aging in humans. Across multiple DNA methylation clocks—including DunedinPACE, GrimAge, and PhenoAge—semaglutide-treated participants showed approximately 9% deceleration in the pace of aging versus placebo, with the strongest signals in inflammation-, brain-, and heart-linked organ-system clocks.